Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04155 (
pS2
)
1,234
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
HMGN1
, an abundant nucleosomal binding protein, can affect both the chromatin higher order structure and the modification of nucleosomal histones, but it alters the expression of only a subset of genes. We investigated specific gene targeting by
HMGN1
in the context of estrogen induction of gene expression. Knockdown and overexpression experiments indicated that
HMGN1
limits the induction of several estrogen-regulated genes, including
TFF1
and FOS, which are induced by estrogen through entirely distinct mechanisms.
HMGN1
specifically interacts with estrogen receptor alpha (ER alpha), both in vitro and in vivo. At the
TFF1
promoter, estrogen increases
HMGN1
association through recruitment by the ER alpha.
HMGN1
S20E/S24E, although deficient in binding nucleosomal DNA, still interacts with ER alpha and, strikingly, still represses estrogen-driven activation of the
TFF1
gene. On the FOS promoter, which lacks the ER alpha binding sites, constitutively bound serum response factor (SRF) mediates estrogen stimulation.
HMGN1
also interacts specifically with SRF, but
HMGN1
S20E/S24E does not. Consistent with the protein interactions, only wild-type
HMGN1
significantly inhibits the estrogen-driven activation of the FOS gene. Mechanistically, the inhibition of estrogen induction of several ER alpha-associated genes, including
TFF1
, by
HMGN1
correlates with decreased levels of acetylation of Lys9 on histone H3. Together, these findings indicate that
HMGN1
regulates the expression of particular genes via specific protein-protein interactions with transcription factors at target gene regulatory regions.
...
PMID:HMGN1 modulates estrogen-mediated transcriptional activation through interactions with specific DNA-binding transcription factors. 1793 9